Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Cancer and Metastasis Reviews
Erschienen in: Cancer and Metastasis Reviews 1-2/2013

01.06.2013 | NON-THEMATIC REVIEW

The role of the tissue omega-6/omega-3 fatty acid ratio in regulating tumor angiogenesis

verfasst von: Jing X. Kang, Angela Liu

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 1-2/2013

Einloggen, um Zugang zu erhalten

Abstract

Angiogenesis is a necessary step in tumor growth and metastasis. It is well established that the metabolites of omega-6 and omega-3 fatty acids, which must be obtained through the diet and cannot be synthesized de novo in mammals, have differential effects on cellular processes. Omega-6 fatty acid (n−6 FA)-derived metabolites promote angiogenesis by increasing growth factor expression whereas omega-3 fatty acids (n−3 FA) have anti-angiogenic and antitumor properties. However, most studies thus far have failed to account for the role of the n−6 FA/n−3 FA ratio in angiogenesis and instead examined the absolute levels of n−6 and n−3 FA. This review highlights the biochemical interactions between n−6 and n−3 FA and focuses on how the n−6/n−3 FA ratio in tissues modulates tumor angiogenesis. We suggest that future work should consider the n−6/n−3 FA ratio to be a key element in experimental design and analysis. Furthermore, we recommend that clinical interventions should aim to both reduce n−6 metabolites and simultaneously increase n−3 FA intake.
Literatur
1.
Arnold, F., & West, D. (1991). Angiogenesis in wound healing. Pharmacology & Theraputics, 52, 407–422.CrossRef
2.
Kleim, J. A., Cooper, N. R., & VandenBerg, P. M. (2002). Exercise induces angiogenesis but does not alter movement representations within rat motor cortex. Brain Research, 934(1), 1–6.PubMedCrossRef
3.
4.
Conway, E. M., Collen, D., & Carmeliet, P. (2001). Molecular mechanisms of blood vessel growth. Cardiovascular Research, 49(3), 507–521.PubMedCrossRef
5.
Folkman, J., Cole, P., & Zimmerman, S. (1966). Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment. Annals of Surgery, 164(3), 491–502.PubMedCrossRef
6.
7.
8.
Blood, C. H., & Zetter, B. R. (1990). Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochimica et Biophysica Acta, 1032(1), 89–118.PubMed
9.
Naumov, G. N., Akslen, L. A., & Folkman, J. (2006). Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle, 5(16), 1779–1787.PubMedCrossRef
10.
Morisada, T., Kubota, Y., Urano, T., Suda, T., & Oike, Y. (2006). Angiopoietins and angiopoietin-like proteins in angiogenesis. Endothelium, 13(2), 71–79.PubMedCrossRef
11.
Rajkumar, T. (2001). Growth factors and growth factor receptors in cancer. Current Science, 81, 535–541.
12.
Wu, Y., & Zhou, B. P. (2010). TNF-alpha/NF-kappaB/Snail pathway in cancer cell migration and invasion. British Journal of Cancer, 102(4), 639–644.PubMedCrossRef
13.
Li, A., Dubey, S., Varney, M. L., Dave, B. J., & Singh, R. K. (2003). IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. Journal of Immunology, 170(6), 3369–3376.
14.
Kang, J. X. (2005). From fat to fat-1: a tale of omega-3 fatty acids. Journal of Membrane Biology, 206(2), 165–172.PubMedCrossRef
15.
Burdge, G. C., & Calder, P. C. (2005). Conversion of alpha-linolenic acid to longer-chain polyunsaturated fatty acids in human adults. Reproduction, Nutrition, Development, 45(5), 581–597.PubMedCrossRef
16.
Hoagland, K. M., Maier, K. G., Moreno, C., Yu, M., & Roman, R. J. (2001). Cytochrome P450 metabolites of arachidonic acid: novel regulators of renal function. Nephrology, Dialysis, Transplantation, 16(12), 2283–2285.PubMedCrossRef
17.
Smith, W. L. (1989). The eicosanoids and their biochemical mechanisms of action. Biochemical Journal, 259(2), 315–324.PubMed
18.
Arita, M., Yoshida, M., Hong, S., Tjonahen, E., Glickman, J. N., Petasis, N. A., et al. (2005). Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proceedings of the National Academy of Sciences of the United States of America, 102(21), 7671–7676.PubMedCrossRef
19.
Bagga, D., Wang, L., Farias-Eisner, R., Glaspy, J. A., & Reddy, S. T. (2003). Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proceedings of the National Academy of Sciences of the United States of America, 100(4), 1751–1756.PubMedCrossRef
20.
Jin, Y., Arita, M., Zhang, Q., Saban, D. R., Chauhan, S. K., Chiang, N., et al. (2009). Anti-angiogenesis effect of the novel anti-inflammatory and pro-resolving lipid mediators. Investigative Ophthalmology and Visual Science, 50(10), 4743–4752.PubMedCrossRef
21.
Kamiyama, M., Pozzi, A., Yang, L., DeBusk, L. M., Breyer, R. M., & Lin, P. C. (2006). EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene, 25(53), 7019–7028.PubMedCrossRef
22.
Nie, D., Lamberti, M., Zacharek, A., Li, L., Szekeres, K., Tang, K., et al. (2000). Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis. Biochemical and Biophysical Research Communications, 267(1), 245–251.PubMedCrossRef
23.
Pai, R., Szabo, I. L., Soreghan, B. A., Atay, S., Kawanaka, H., & Tarnawski, A. S. (2001). PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. Biochemical and Biophysical Research Communications, 286(5), 923–928.PubMedCrossRef
24.
Pola, R., Gaetani, E., Flex, A., Aprahamian, T. R., Bosch-Marce, M., Losordo, D. W., et al. (2004). Comparative analysis of the in vivo angiogenic properties of stable prostacyclin analogs: a possible role for peroxisome proliferator-activated receptors. Journal of Molecular and Cellular Cardiology, 36(3), 363–370.PubMedCrossRef
25.
Grimminger, F., Wahn, H., Mayer, K., Kiss, L., Walmrath, D., & Seeger, W. (1997). Impact of arachidonic versus eicosapentaenoic acid on exotonin-induced lung vascular leakage: relation to 4-series versus 5-series leukotriene generation. American Journal of Respiratory and Critical Care Medicine, 155(2), 513–519.PubMedCrossRef
26.
Samuelsson, B. (1983). Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science, 220(4597), 568–575.PubMedCrossRef
27.
Yuan, Y. M., Fang, S. H., Qian, X. D., Liu, L. Y., Xu, L. H., Shi, W. Z., et al. (2009). Leukotriene D4 stimulates the migration but not proliferation of endothelial cells mediated by the cysteinyl leukotriene cyslt(1) receptor via the extracellular signal-regulated kinase pathway. Journal of Pharmacological Sciences, 109(2), 285–292.PubMedCrossRef
28.
Spencer, L., Mann, C., Metcalfe, M., Webb, M. B., Pollard, C., Spencer, D., et al. (2009). The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. European Journal of Cancer, 45(19493674), 2077–2086.PubMedCrossRef
29.
Kang, J. X., & Weylandt, K. H. (2008). Modulation of inflammatory cytokines by omega-3 fatty acids. Sub-Cellular Biochemistry, 49(18751910), 133–143.PubMedCrossRef
30.
Kang, J. X. (2011). Omega-3: a link between global climate change and human health. Biotechnology Advances, 29(4), 388–390.PubMedCrossRef
31.
Simopoulos, A. P. (2002). Omega-3 fatty acids in inflammation and autoimmune diseases. Journal of the American College of Nutrition, 21(6), 495–505.PubMed
32.
Simopoulos, A. P. (2006). Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomedicine and Pharmacotherapy, 60(9), 502–507.CrossRef
33.
Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10(3), 181–193.PubMedCrossRef
34.
Gately, S., & Li, W. W. (2004). Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Seminars in Oncology, 31(2 Suppl 7), 2–11.PubMedCrossRef
35.
Soslow, R. A., Dannenberg, A. J., Rush, D., Woerner, B. M., Khan, K. N., Masferrer, J., et al. (2000). COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer, 89(12), 2637–2645.PubMedCrossRef
36.
Gallo, O., Franchi, A., Magnelli, L., Sardi, I., Vannacci, A., Boddi, V., et al. (2001). Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia, 3(1), 53–61.
37.
Greenhough, A., Smartt, H. J., Moore, A. E., Roberts, H. R., Williams, A. C., Paraskeva, C., et al. (2009). The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 30(3), 377–386.PubMedCrossRef
38.
Kaidi, A., Qualtrough, D., Williams, A. C., & Paraskeva, C. (2006). Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxia-inducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Research, 66(13), 6683–6691.PubMedCrossRef
39.
Kyzas, P. A., Stefanou, D., & Agnantis, N. J. (2005). COX-2 expression correlates with VEGF-C and lymph node metastases in patients with head and neck squamous cell carcinoma. Modern Pathology, 18(1), 153–160.PubMedCrossRef
40.
Su, J. L., Shih, J. Y., Yen, M. L., Jeng, Y. M., Chang, C. C., Hsieh, C. Y., et al. (2004). Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. Cancer Research, 64(2), 554–564.PubMedCrossRef
41.
Chien, M. H., Ku, C. C., Johansson, G., Chen, M. W., Hsiao, M., Su, J. L., et al. (2009). Vascular endothelial growth factor-C (VEGF-C) promotes angiogenesis by induction of COX-2 in leukemic cells via the VEGF-R3/JNK/AP-1 pathway. Carcinogenesis, 30(12), 2005–2013.PubMedCrossRef
42.
Lala, P. K., Al-Mutter, N., & Orucevic, A. (1997). Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. International Journal of Cancer, 73(3), 371–380.CrossRef
43.
Yoshida, S., Amano, H., Hayashi, I., Kitasato, H., Kamata, M., Inukai, M., et al. (2003). COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo. Laboratory Investigation, 83(10), 1385–1394.PubMedCrossRef
44.
Timoshenko, A. V., Chakraborty, C., Wagner, G. F., & Lala, P. K. (2006). COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer. British Journal of Cancer, 94(8), 1154–1163.PubMedCrossRef
45.
Honn, K. V., Tang, D. G., Gao, X., Butovich, I. A., Liu, B., Timar, J., et al. (1994). 12-lipoxygenases and 12(S)-HETE: role in cancer metastasis. Cancer and Metastasis Reviews, 13(3–4), 365–396.PubMedCrossRef
46.
Nie, D., Hillman, G. G., Geddes, T., Tang, K., Pierson, C., Grignon, D. J., et al. (1998). Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Research, 58(18), 4047–4051.PubMed
47.
Chatterjee, M., Das, S., Roy, K., & Chatterjee, M. (2011). Overexpression of 5-lipoxygenase and its relation with cell proliferation and angiogenesis in 7,12-dimethylbenz(alpha)anthracene-induced rat mammary carcinogenesis. Molecular Carcinogenesis. doi:10.​1002/​mc.​21858.
48.
Ye, Y. N., Liu, E. S., Shin, V. Y., Wu, W. K., & Cho, C. H. (2004). Contributory role of 5-lipoxygenase and its association with angiogenesis in the promotion of inflammation-associated colonic tumorigenesis by cigarette smoking. Toxicology, 203(1–3), 179–188.PubMedCrossRef
49.
Romano, M., & Claria, J. (2003). Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. The FASEB Journal, 17(14), 1986–1995.CrossRef
50.
Webler, A. C., Michaelis, U. R., Popp, R., Barbosa-Sicard, E., Murugan, A., Falck, J. R., et al. (2008). Epoxyeicosatrienoic acids are part of the VEGF-activated signaling cascade leading to angiogenesis. American Journal of Physiology. Cell Physiology, 295(5), C1292–C1301.PubMedCrossRef
51.
Michaelis, U. R., Fisslthaler, B., Barbosa-Sicard, E., Falck, J. R., Fleming, I., & Busse, R. (2005). Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. Journal of Cell Science, 118(Pt 23), 5489–5498.PubMedCrossRef
52.
Wang, Y., Wei, X., Xiao, X., Hui, R., Card, J. W., Carey, M. A., et al. (2005). Arachidonic acid epoxygenase metabolites stimulate endothelial cell growth and angiogenesis via mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways. Journal of Pharmacology and Experimental Therapeutics, 314(2), 522–532.PubMedCrossRef
53.
Hyde, C. A., & Missailidis, S. (2009). Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumour-angiogenesis. International Immunopharmacology, 9(6), 701–715.PubMedCrossRef
54.
James, M. J., Gibson, R. A., & Cleland, L. G. (2000). Dietary polyunsaturated fatty acids and inflammatory mediator production. American Journal of Clinical Nutrition, 71(1 Suppl), 343S–348S.PubMed
55.
Chen, Z. Y., & Istfan, N. W. (2000). Docosahexaenoic acid is a potent inducer of apoptosis in HT-29 colon cancer cells. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 63(5), 301–308.PubMedCrossRef
56.
Larsson, S. C., Kumlin, M., Ingelman-Sundberg, M., & Wolk, A. (2004). Dietary long-chain n−3 fatty acids for the prevention of cancer: a review of potential mechanisms. American Journal of Clinical Nutrition, 79(6), 935–945.PubMed
57.
Ambring, A., Johansson, M., Axelsen, M., Gan, L., Strandvik, B., & Friberg, P. (2006). Mediterranean-inspired diet lowers the ratio of serum phospholipid n−6 to n−3 fatty acids, the number of leukocytes and platelets, and vascular endothelial growth factor in healthy subjects. American Journal of Clinical Nutrition, 83(3), 575–581.PubMed
58.
Spencer, L., Mann, C., Metcalfe, M., Webb, M., Pollard, C., Spencer, D., et al. (2009). The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. European Journal of Cancer, 45(12), 2077–2086.PubMedCrossRef
59.
Connor, K. M., SanGiovanni, J. P., Lofqvist, C., Aderman, C. M., Chen, J., Higuchi, A., et al. (2007). Increased dietary intake of omega-3-polyunsaturated fatty acids reduces pathological retinal angiogenesis. Nature Medicine, 13(17589522), 868–873.PubMedCrossRef
60.
Kang, J. X., & Weylandt, K. H. (2008). Modulation of inflammatory cytokines by omega-3 fatty acids. Sub-Cellular Biochemistry, 49, 133–143.PubMedCrossRef
61.
De Caterina, R., & Massaro, M. (2005). Omega-3 fatty acids and the regulation of expression of endothelial pro-atherogenic and pro-inflammatory genes. Journal of Membrane Biology, 206(2), 103–116.PubMedCrossRef
62.
Weylandt, K. H., & Kang, J. X. (2005). Rethinking lipid mediators. The Lancet, 366(9486), 618–620.CrossRef
63.
Wan, J. B., Huang, L. L., Rong, R., Tan, R., Wang, J., & Kang, J. X. (2010). Endogenously decreasing tissue n−6/n−3 fatty acid ratio reduces atherosclerotic lesions in apolipoprotein E-deficient mice by inhibiting systemic and vascular inflammation. Arteriosclerosis, Thrombosis, and Vascular Biology, 30(12), 2487–2494.PubMedCrossRef
64.
Schmocker, C., Weylandt, K. H., Kahlke, L., Wang, J., Lobeck, H., Tiegs, G., et al. (2007). Omega-3 fatty acids alleviate chemically induced acute hepatitis by suppression of cytokines. Hepatology, 45(4), 864–869.PubMedCrossRef
65.
Bilal, S., Haworth, O., Wu, L., Weylandt, K. H., Levy, B. D., & Kang, J. X. (2011). Fat-1 transgenic mice with elevated omega-3 fatty acids are protected from allergic airway responses. Biochimica et Biophysica Acta, 1812(9), 1164–1169.PubMedCrossRef
66.
Weylandt, K. H., Nadolny, A., Kahlke, L., Kohnke, T., Schmocker, C., Wang, J., et al. (2008). Reduction of inflammation and chronic tissue damage by omega-3 fatty acids in fat-1 transgenic mice with pancreatitis. Biochimica et Biophysica Acta, 1782(11), 634–641.PubMedCrossRef
67.
Jia, Q., Lupton, J. R., Smith, R., Weeks, B. R., Callaway, E., Davidson, L. A., et al. (2008). Reduced colitis-associated colon cancer in fat-1 (n−3 fatty acid desaturase) transgenic mice. Cancer Research, 68(18483285), 3985–3991.PubMedCrossRef
68.
White, P. J., Arita, M., Taguchi, R., Kang, J. X., & Marette, A. (2010). Transgenic restoration of long-chain n−3 fatty acids in insulin target tissues improves resolution capacity and alleviates obesity-linked inflammation and insulin resistance in high-fat-fed mice. Diabetes, 59(12), 3066–3073.PubMedCrossRef
69.
Wada, S., Yamazaki, T., Kawano, Y., Miura, S., & Ezaki, O. (2008). Fish oil fed prior to ethanol administration prevents acute ethanol-induced fatty liver in mice. Journal of Hepatology, 49(3), 441–450.PubMedCrossRef
70.
McCusker, M. M., & Grant-Kels, J. M. (2010). Healing fats of the skin: the structural and immunologic roles of the omega-6 and omega-3 fatty acids. Clinics in Dermatology, 28(4), 440–451.PubMedCrossRef
71.
Wright, S. A., O’Prey, F. M., McHenry, M. T., Leahey, W. J., Devine, A. B., Duffy, E. M., et al. (2008). A randomised interventional trial of omega-3-polyunsaturated fatty acids on endothelial function and disease activity in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 67(6), 841–848.PubMedCrossRef
72.
Wang, D., & Dubois, R. N. (2010). Eicosanoids and cancer. Nature Reviews. Cancer, 10(20168319), 181–193.PubMedCrossRef
73.
Jackson, J. R., Seed, M. P., Kircher, C. H., Willoughby, D. A., & Winkler, J. D. (1997). The codependence of angiogenesis and chronic inflammation. The FASEB Journal, 11(6), 457–465.
74.
Carmeliet, P., & Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature, 407(6801), 249–257.PubMedCrossRef
75.
Voronov, E., Shouval, D. S., Krelin, Y., Cagnano, E., Benharroch, D., Iwakura, Y., et al. (2003). IL-1 is required for tumor invasiveness and angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 100(5), 2645–2650.PubMedCrossRef
76.
Firestein, G. S. (1999). Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. Journal of Clinical Investigation, 103(1), 3–4.PubMedCrossRef
77.
Storgard, C. M., Stupack, D. G., Jonczyk, A., Goodman, S. L., Fox, R. I., & Cheresh, D. A. (1999). Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. Journal of Clinical Investigation, 103(1), 47–54.PubMedCrossRef
78.
MacLean, C. H., Newberry, S. J., Mojica, W. A., Khanna, P., Issa, A. M., Suttorp, M. J., et al. (2006). Effects of omega-3 fatty acids on cancer risk: a systematic review. JAMA : The Journal of the American Medical Association, 295(4), 403–415.CrossRef
79.
Terry, P., Bergkvist, L., Holmberg, L., & Wolk, A. (2001). No association between fat and fatty acids intake and risk of colorectal cancer. Cancer Epidemiology, Biomarkers & Prevention, 10(8), 913–914.
80.
Godley, P. A., Campbell, M. K., Gallagher, P., Martinson, F. E., Mohler, J. L., & Sandler, R. S. (1996). Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. Cancer Epidemiology, Biomarkers & Prevention, 5(11), 889–895.
81.
Ramon, J. M., Bou, R., Romea, S., Alkiza, M. E., Jacas, M., Ribes, J., et al. (2000). Dietary fat intake and prostate cancer risk: a case–control study in Spain. Cancer Causes & Control, 11(8), 679–685.CrossRef
82.
Leitzmann, M. F., Stampfer, M. J., Michaud, D. S., Augustsson, K., Colditz, G. C., Willett, W. C., et al. (2004). Dietary intake of n−3 and n−6 fatty acids and the risk of prostate cancer. American Journal of Clinical Nutrition, 80(1), 204–216.PubMed
83.
Simonsen, N., van’t Veer, P., Strain, J. J., Martin-Moreno, J. M., Huttunen, J. K., & Navajas, J. F. (1998). Adipose tissue omega-3 and omega-6 fatty acid content and breast cancer in the EURAMIC study. European Community Multicenter Study on Antioxidants, Myocardial Infarction, and Breast Cancer. American Journal of Epidemiology, 147(4), 342–352.PubMedCrossRef
84.
Maillard, V., Bougnoux, P., Ferrari, P., Jourdan, M. L., Pinault, M., Lavillonniere, F., et al. (2002). N−3 and N−6 fatty acids in breast adipose tissue and relative risk of breast cancer in a case–control study in Tours, France. International Journal of Cancer, 98(1), 78–83.CrossRef
85.
Williams, C. D., Whitley, B. M., Hoyo, C., Grant, D. J., Iraggi, J. D., Newman, K. A., et al. (2011). A high ratio of dietary n−6/n−3 polyunsaturated fatty acids is associated with increased risk of prostate cancer. Nutrition Research, 31(1), 1–8.PubMedCrossRef
86.
Kang, J. X. (2007). Fat-1 transgenic mice: a new model for omega-3 research. Prostaglandins, Leukotrienes, and Essential Fatty Acids, 77(5–6), 263–267.PubMedCrossRef
87.
Hudert, C. A., Weylandt, K. H., Lu, Y., Wang, J., Hong, S., Dignass, A., et al. (2006). Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proceedings of the National Academy of Sciences of the United States of America, 103(30), 11276–11281.PubMedCrossRef
88.
Xia, S., Lu, Y., Wang, J., He, C., Hong, S., Serhan, C. N., et al. (2006). Melanoma growth is reduced in fat-1 transgenic mice: impact of omega-6/omega-3 essential fatty acids. Proceedings of the National Academy of Sciences of the United States of America, 103(33), 12499–12504.PubMedCrossRef
89.
Berquin, I. M., Min, Y., Wu, R., Wu, J., Perry, D., Cline, J. M., et al. (2007). Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. Journal of Clinical Investigation, 117(7), 1866–1875.PubMedCrossRef
90.
Griffitts, J., Saunders, D., Tesiram, Y. A., Reid, G. E., Salih, A., Liu, S., et al. (2010). Non-mammalian fat-1 gene prevents neoplasia when introduced to a mouse hepatocarcinogenesis model: omega-3 fatty acids prevent liver neoplasia. Biochimica et Biophysica Acta, 1801(10), 1133–1144.PubMedCrossRef
91.
Jia, Q., Lupton, J. R., Smith, R., Weeks, B. R., Callaway, E., Davidson, L. A., et al. (2008). Reduced colitis-associated colon cancer in fat-1 (n−3 fatty acid desaturase) transgenic mice. Cancer Research, 68(10), 3985–3991.PubMedCrossRef
92.
Kang, J. X., Wang, J., Wu, L., & Kang, Z. B. (2004). Transgenic mice: fat-1 mice convert n−6 to n−3 fatty acids. Nature, 427(6974), 504.PubMedCrossRef
93.
Lim, K., Han, C., Dai, Y., Shen, M., & Wu, T. (2009). Omega-3 polyunsaturated fatty acids inhibit hepatocellular carcinoma cell growth through blocking beta-catenin and cyclooxygenase-2. Molecular Cancer Therapeutics, 8(11), 3046–3055.PubMedCrossRef
94.
Lu, Y., Nie, D., Witt, W. T., Chen, Q., Shen, M., Xie, H., et al. (2008). Expression of the fat-1 gene diminishes prostate cancer growth in vivo through enhancing apoptosis and inhibiting GSK-3 beta phosphorylation. Molecular Cancer Therapeutics, 7(10), 3203–3211.PubMedCrossRef
95.
Nowak, J., Weylandt, K. H., Habbel, P., Wang, J., Dignass, A., Glickman, J. N., et al. (2007). Colitis-associated colon tumorigenesis is suppressed in transgenic mice rich in endogenous n−3 fatty acids. Carcinogenesis, 28(9), 1991–1995.PubMedCrossRef
96.
Weylandt, K. H., Krause, L. F., Gomolka, B., Chiu, C. Y., Bilal, S., Nadolny, A., et al. (2011). Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-alpha. Carcinogenesis, 32(6), 897–903.PubMedCrossRef
97.
Giovannucci, E., Rimm, E. B., Stampfer, M. J., Colditz, G. A., Ascherio, A., & Willett, W. C. (1994). Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Annals of Internal Medicine, 121(4), 241–246.PubMedCrossRef
98.
Wallace, J. M. (2002). Nutritional and botanical modulation of the inflammatory cascade—eicosanoids, cyclooxygenases, and lipoxygenases—as an adjunct in cancer therapy. Integrative Cancer Therapies, 1(1), 7–37.PubMed
99.
Gogos, C. A., Ginopoulos, P., Salsa, B., Apostolidou, E., Zoumbos, N. C., & Kalfarentzos, F. (1998). Dietary omega-3 polyunsaturated fatty acids plus vitamin E restore immunodeficiency and prolong survival for severely ill patients with generalized malignancy: a randomized control trial. Cancer, 82(2), 395–402.PubMedCrossRef
100.
Okamoto, Y., Okano, K., Izuishi, K., Usuki, H., Wakabayashi, H., & Suzuki, Y. (2009). Attenuation of the systemic inflammatory response and infectious complications after gastrectomy with preoperative oral arginine and omega-3 fatty acids supplemented immunonutrition. World Journal of Surgery, 33(9), 1815–1821.PubMedCrossRef
101.
Wigmore, S. J., Barber, M. D., Ross, J. A., Tisdale, M. J., & Fearon, K. C. (2000). Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutrition and Cancer, 36(2), 177–184.PubMedCrossRef
Metadaten
Titel
The role of the tissue omega-6/omega-3 fatty acid ratio in regulating tumor angiogenesis
verfasst von
Jing X. Kang
Angela Liu
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Cancer and Metastasis Reviews / Ausgabe 1-2/2013
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-012-9401-9

Weitere Artikel der Ausgabe 1-2/2013

Cancer and Metastasis Reviews 1-2/2013 Zur Ausgabe

NON-THEMATIC REVIEW

Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials

OriginalPaper

What underlies the diversity of brain tumors?

OriginalPaper

Mouse models of BRCA1 and their application to breast cancer research

NON-THEMATIC REVIEW

Bone marrow microenvironment in cancer patients: immunological aspects and clinical implications

Announcement

Biography—Yong Q. Chen

NON-THEMATIC REVIEW

Tackling hepatitis B virus-associated hepatocellular carcinoma—the future is now

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise